Filovirus rVSV Vaccines Michael A. Egan, Ph.D. Director of - - PowerPoint PPT Presentation

▶
filovirus rvsv vaccines
SMART_READER_LITE
LIVE PREVIEW

Filovirus rVSV Vaccines Michael A. Egan, Ph.D. Director of - - PowerPoint PPT Presentation

May 06, 2023 153 likes •618 views

Filovirus rVSV Vaccines Michael A. Egan, Ph.D. Director of Immunology 1 Proprietary and confidential. Do not distribute. | Presentation Outline: 1.) Background on the VesiculoVax Vaccine Platform 2.) Ability of a Single Dose

slide-1
SLIDE 1

Proprietary and confidential. Do not distribute. |

Filovirus rVSV Vaccines

  • Michael A. Egan, Ph.D.
  • Director of Immunology

1

slide-2
SLIDE 2

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

2

slide-3
SLIDE 3

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

3

slide-4
SLIDE 4

Proprietary and confidential. Do not distribute. |

VesiculoVax™: A Family of Vaccine Vectors

N P M G L

Envelope RNA genome 4Nonsegmented, 4Single-stranded 4Negative-sense Nucleocapsid Phosphoprotein Matrix protein G protein Large protein (RNA Pol)

Intergenic Stop/Start

G protein 4Mediates cell attachment 4Target of neutralizing antibodies

4

1 2 3 4 5

slide-5
SLIDE 5

Proprietary and confidential. Do not distribute. |

The Vesiculovirus mRNA Transcriptional Gradient

N P M G L

Intergenic Stop/Start mRNA transcription (+) genome synthesis

5

1 2 3 4 5

slide-6
SLIDE 6

Proprietary and confidential. Do not distribute. |

N P M G L

mRNA transcription (+) genome synthesis

CT1

Filo GP Filo GP Using the Vesiculovirus mRNA Transcriptional Gradient to Attenuate the Vector and Overexpress a Gene of Interest

6

1 2 3 4 6 5

N gene shuffle Truncation of G protein cytoplasmic tail (CT1)

slide-7
SLIDE 7

Proprietary and confidential. Do not distribute. |

VesiculoVax™ Vectored Vaccines

Immunogenicity

  • Replication competent vectors
  • Targets antigen-presenting cells
  • Attenuating mutations increase immunogenicity

Manufacturing

  • Propagates efficiently in PBS certified Vero production cell line
  • GMP Manufacturing and purification processes in place

Vector Immunity

  • Little pre-existing immunity in the human population
  • Clinical demonstration of effective homologous boosting

7

Single Stranded/Non-segmented/Negative-sense RNA Viruses

  • Small simple genome, large capacity for inserting multiple foreign genes
  • Modulation of antigen expression controlled by gene position
  • Synergistic attenuating mutations:
  • [N gene shuffle (N4) & G protein CT truncation (CT1)
  • Family of non-cross-reactive (both B and T cell) vectors
  • Four reduced to practice and three under development
slide-8
SLIDE 8

Proprietary and confidential. Do not distribute. |

VesiculoVax™ Vectored Vaccines

rVSV N4CT1 Clinical Status

  • HVTN-090
  • FIM dose escalation, N=60, 104 – 108 PFU
  • 100% seroconversion, 63% ELISpot response rate, homologous boosting induces anamnestic response
  • Safe and well tolerated, no vaccine-related SAE
  • HVTN-087
  • pDNA prime / rVSV boost, N=100, 108 PFU
  • 92% CD4 ICS response rate, 58% CD8 ICS response rate, highest ICS response rate in any HVTN trial
  • Safe and well tolerated, no vaccine-related SAE
  • TheraVax
  • pDNA prime / rVSV boost, N=30, 107 PFU
  • Study is on-going
  • Safe and well tolerated, no vaccine-related SAE
  • HVTN-112
  • pDNA prime / rVSV boost, N=15, 107 PFU
  • Study is on-going
  • EBOV-001
  • FIM dose escalation, N=39, 104 – 106 PFU
  • Study is on-going

8

slide-9
SLIDE 9

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

9

slide-10
SLIDE 10

Proprietary and confidential. Do not distribute. |

rVSV Vectored Tri-Valent Filovirus Vaccine Candidate

P M N GIN L

3 1 2 4 6 5

Le Tr

CT1

EBOV GP

rVSVN4CT1-panFiloGP

P M N GIN L

3 1 2 4 6 5

Le Tr

CT1

SUDV GP P M N GIN L

3 1 2 4 6 5

Le Tr

CT1

MARV GP

10

slide-11
SLIDE 11

Proprietary and confidential. Do not distribute. |

Iteration Group Vaccine Dose (PFU) Animals Vacc. Day 1,000 PFU IM Virus Challenge Day 28 M F 1 1 Tri-val N4CT1 panFiloGP(a1) 3 x 107 3 2 EBOV (Kikwit) 2 N4CT1-HIVgag(s1) 3 x 107 1 1 2 3 Tri-val N4CT1 panFiloGP(a1) 3 x 107 3 2 SUDV (Gulu) 4 N4CT1-HIVgag(s1) 3 x 107 1 1 3 5 Tri-val N4CT1 panFiloGP(a1) 3 x 107 3 2 MARV (Angola) 6 N4CT1-HIVgag(s1) 3 x 107 1 1

Single Dose NHP Immunogenicity/Efficacy Trial of Tri-Valent rVSVN4CT1-panFilovirus Vaccine

11

slide-12
SLIDE 12

Proprietary and confidential. Do not distribute. |

Efficacy of a Single Dose Tri-Valent rVSVN4CT1-panFilovirus Vaccine in NHPs

Low Passage 7U EBOV Challenge 1,000 PFU IM Low Passage SUDV Challenge 1,000 PFU IM Low Passage MARV Challenge 1,000 PFU IM

20 40 60 80 100 120 10 20 30 rVSVN4CT1-panFiloGP (N=5) rVSVN4CT1-HIVgag (N=2)

Day post challenge

20 40 60 80 100 120 10 20 30 rVSVN4CT1- panFiloGP (N=5) rVSVN4CT1-HIVgag (N=2) 20 40 60 80 100 120 10 20 30 rVSVN4CT1- panFiloGP (N=5) rVSVN4CT1-HIVgag (N=2)

% Survival

12

slide-13
SLIDE 13

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

13

slide-14
SLIDE 14

Proprietary and confidential. Do not distribute. |

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects

IND No.: BB-IND-16670 Phase: 1 Protocol Number: rVSV-EBOV-01

14

slide-15
SLIDE 15

Proprietary and confidential. Do not distribute. |

Phase 1 Dose Escalation and Vaccination Schedule in Months (Days)

Study Arm N Dose Month 0 (Day 0) Month 1 (Day 28) Group 1

10 2.5 x 104 PFU rVSVN4CT1-EBOVGP1 rVSVN4CT1-EBOVGP1 3 — control (saline) control (saline)

Group 2

10 2.5 x 105 PFU rVSVN4CT1-EBOVGP1 rVSVN4CT1-EBOVGP1 3 — control (saline) control (saline)

Group 3

10 2.0 x 106 PFU rVSVN4CT1-EBOVGP1 rVSVN4CT1-EBOVGP1 3 — control (saline) control (saline)

Total

39 (30 vaccine/9 placebo)

Notes: All immunizations will be administered IM in the deltoid; for Groups 1 and 2 each dose will be delivered bi- laterally as 2 x 0.5 mL inoculations, and for Group 3 as 2 x 1.0 ml inoculations; CoA = Certificate of Analysis; PFU = plaques forming units.

Protocol Number: rVSV-EBOV-01

15

slide-16
SLIDE 16

Proprietary and confidential. Do not distribute. | 2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 4 5 2 6 7 2 2 4 3

# AEs

Injection site pain/tenderness

Grade 1 Grade 2 13 subjects/16 related AEs 2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 3 5 # AEs

Nausea

Grade 1 Grade 2 3 subjects/7 related, 1 unlikely related AEs

Protocol Number: rVSV-EBOV-01: Adverse Events

From blinded data (Active and Placebo), excluding AEs considered unrelated.

16

slide-17
SLIDE 17

Proprietary and confidential. Do not distribute. | 2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 1 2 # AEs

Muscle pain/Myalgia

Grade 1 Grade 2 3 subjects/3 related AEs 2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 1 2 # AEs

Increased WBC

Grade 1 Grade 2 2 subjects/3 unlikely related AEs 2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 1 2 # AEs

Bruise/Erythema

Grade 1 Grade 2 2 subjects/3 related AEs

Protocol Number: rVSV-EBOV-01: Adverse Events

2 4 6 8 10 Vax1 Vax2 Vax1 Vax2 Vax1 Vax2 Cohort 1 Cohort 2 Cohort 3 1 1 # AEs

Arthralgia

Grade 1 Grade 2 2 subjects/2 related AEs

17

slide-18
SLIDE 18

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

Detection of Disseminated Vaccine Virus (Blinded)

Sample Day Blood Urine Saliva

RT-qPCR

(LOQ=1.36x103 copies/mL)

Culture Confirmed

(LOD=100 PFU/0.1 mL)

RT-qPCR

(LOQ=6.43x103 copies/mL)

Culture Confirmed

(LOD=100 PFU/0.1 mL)

RT-qPCR

(LOQ=8.30x102 copies/mL)

Culture Confirmed

(LOD=100 PFU/0.1 mL)

0 (Prime) 0/39 NA 0/39 NA 0/39 NA 1 1a/39 Neg 0/39 NA 0/39 NA 3 0/39 NA 0/39 NA 0/39 NA 7 0/39 NA 0/39 NA 0/39 NA 14 0/39 NA 0/39 NA 0/39 NA 28 (Boost) 0/39 NA 0/39 NA 0/39 NA 29 0/38 NA 0/38 NA 0/38 NA 31 0/38 NA 0/38 NA 0/38 NA 35 0/38 NA 0/38 NA 0/38 NA 42 0/38 NA 0/38 NA 0/38 NA 56 0/38 NA 0/38 NA 0/38 NA

a2.66 x 103 copies/mL

18

slide-19
SLIDE 19

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

EBOV GP-specific ELISpot analysis conducted by Profectus BioSciences

Cryo-preserved PBMCs were collected at the following time points for ELISpot analysis: Visit 2: Day of 1st vaccination Visit 5: 1 week post 1st vaccination Visit 6: 2 weeks post 1st vaccination Visit 7: Day of 2nd vaccination Visit 10: 1 week post 2nd vaccination Visit 11: 2 weeks post 2nd vaccination Visit 12: 4 weeks post 2nd vaccination Visit 13: 22 weeks post 2nd vaccination

19

slide-20
SLIDE 20

Proprietary and confidential. Do not distribute. | 50 100 150 200 250 300 350 400 450 20 40 60 80 100 120 140 160 180 200 Grp 1: 2.5x10^4 PFU Grp 2: 2.5x10^5 PFU Grp 3: 2.0x10^6 PFU

EBOV GP-specific ELISpot Response (SFC/106 PBMCs)

6 of 13 (46%) 8 of 12 (67%)

Protocol Number: rVSV-EBOV-01

BLINDED EBOV GP-specific cell mediated immune (CMI) responses

  • ver time by IFN-gamma ELISpot assay

9 of 13 (69%) Responder Freq

Human ELISpot assay positivity criteria:

  • ≥ Assay LOB (80 SFC/106 PBMCs for EBOV GP)
  • ≥ 2x baseline visit 2 response

Study Day

20

slide-21
SLIDE 21

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

EBOV GP-specific ELISA analysis conducted by Battelle

Serum was collected at the following time points for ELISA analysis: Visit 2: Day of 1st vaccination Visit 5: 1 week post 1st vaccination Visit 6: 2 weeks post 1st vaccination Visit 7: Day of 2nd vaccination Visit 10: 1 week post 2nd vaccination Visit 11: 2 weeks post 2nd vaccination Visit 12: 4 weeks post 2nd vaccination Visit 13: 22 weeks post 2nd vaccination

21

slide-22
SLIDE 22

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

EBOV GP-specific ELISA responses Cohort #1: 2.5x104 PFU dose level

V2: baseline V5: 1wk post 1st vacc V6: 2wk post 1st vacc V7: 4wk post 1st vacc V10: 1wk post 2nd vacc V11: 2wk post 2nd vacc V12: 4wk post 2nd vacc V13: 22wk post 2nd vacc

10 of 13 (77%) Responder Freq

22

slide-23
SLIDE 23

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

EBOV GP-specific ELISA responses Cohort #2: 2.5x105 PFU dose level

V2: baseline V5: 1wk post 1st vacc V6: 2wk post 1st vacc V7: 4wk post 1st vacc V10: 1wk post 2nd vacc V11: 2wk post 2nd vacc V12: 4wk post 2nd vacc V13: 22wk post 2nd vacc

10 of 13 (77%) Responder Freq

23

slide-24
SLIDE 24

Proprietary and confidential. Do not distribute. |

Protocol Number: rVSV-EBOV-01

EBOV GP-specific ELISA responses Cohort #3: 2.0x106 PFU dose level

V2: baseline V5: 1wk post 1st vacc V6: 2wk post 1st vacc V7: 4wk post 1st vacc V10: 1wk post 2nd vacc V11: 2wk post 2nd vacc V12: 4wk post 2nd vacc V13: 22wk post 2nd vac

10 of 13 (77%) Responder Freq

24

slide-25
SLIDE 25

Proprietary and confidential. Do not distribute. |

ELISA Units/mL

Protocol Number: rVSV-EBOV-01

BLINDED Mean EBOV GP-specific ELISA responses over time

1 10 100 1000 10000 100000 20 40 60 80 100 120 140 160 180 200 Grp 1: 2.5x10^4 PFU Grp 2: 2.5x10^5 PFU Grp 3: 2.0x10^6 PFU

25

10 of 13 (77%) 9 of 12 (75%) 10 of 13 (77%) Responder Freq

slide-26
SLIDE 26

Proprietary and confidential. Do not distribute. |

rVSV-EBOV-01 Summary

  • Safe and well-tolerated at all tested doses

§

No vaccine-related AEs greater than grade 2

§

13/39 reported mild to moderate injection site tenderness

§

No other AEs reported in more than 5/39 subjects

§

Vaccine shedding:

§

1 blood sample PCR positive, culture negative

§

PCR and culture of urine and saliva, universally negative

  • Immunogenic at all tested doses and blinded data

consistent with:

§

CMI responses by IFNg ELISpot

  • Response rates of 60-80% post dose 1 and 80-90% post dose 2

§

Antibody responses by ELISA

  • Response rates of 70-100% post dose 1 and 100% post dose 2

26

slide-27
SLIDE 27

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

27

slide-28
SLIDE 28

Proprietary and confidential. Do not distribute. |

Group Number

  • f NHPs

Dosing Material Vaccine Dosage (PFU) Vaccination (Day/Route) Challenge 1,000 PFU MARV (Day/Route) 1 5 Tri-val rVSVN4CT1 panFiloGP(a1) 7.5 x 106 0 / IM 42 / Aerosol 2 5 7.5 x 105 3 5 7.5 x 104 4 5 7.5 x 103 5 4 7.5 x 102 6 2 N4CT1-HIVgag(s1) 7.5 x 106

Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs

28

N=26 Goal: to achieve a wide range of:

  • MARV GP-specific immune responses
  • Post MARV challenge protection
slide-29
SLIDE 29

Proprietary and confidential. Do not distribute. | 29

Anti-EBOV GP ELISA titers

200 400 600 800 1000 1200

  • 20
  • 10

10 20 30 40 7.5 x 10^6 7.5 x 10^5 7.5 x 10^4 7.5 x 10^3 7.5 x 10^2 Control

Days post immunization ELISA units/mL

105 106 102 104 103 Con

slide-30
SLIDE 30

Proprietary and confidential. Do not distribute. | 30

Days post immunization ELISA units/mL

20 40 60 80 100 120 140

  • 20
  • 10

10 20 30 40 7.5 x 10^6 7.5 x 10^5 7.5 x 10^4 7.5 x 10^3 7.5 x 10^2 Control

Anti-SUDV GP ELISA titers

105 106 102 104 103 Con

slide-31
SLIDE 31

Proprietary and confidential. Do not distribute. | 31

Days post immunization ELISA units/mL

50 100 150 200 250

  • 20
  • 10

10 20 30 40 7.5 x 10^6 7.5 x 10^5 7.5 x 10^4 7.5 x 10^3 7.5 x 10^2 Control

Anti-MARV GP ELISA titers

105 106 103 Con

slide-32
SLIDE 32

Proprietary and confidential. Do not distribute. | 32

Vaccine Dose Group Animal ID PRNT50 - Day 35 Ebov Sudv Marv Tri-val N4CT1(6)GP(a1) 7.5 x 106 1 0912162 147.0 29.7 34 1 C65665 77.6 37.9 27 1 C62625 16.5 21.7 10 1 C64284 75.3 23.3 10 1 C68268 91.0 35.8 10 Tri-val N4CT1(6)GP(a1) 7.5 x 105 2 C69902 22.9 29.8 10 2 C56365 178.1 41.2 24 2 C71818 31.4 27.4 10 2 C65896 121.5 26.2 19 2 C66560 110.0 24.3 12 Tri-val N4CT1(6)GP(a1) 7.5 x 104 3 C65897 58.5 19.5 10 3 C64685 19.8 48.4 10 3 C69099 10.9 16.4 10 3 C66181 22.9 29.8 10 3 C65581 24.2 24.5 10 Tri-val N4CT1(6)GP(a1) 7.5 x 103 4 C65889 16.4 16.5 10 4 C66095 37.9 17.7 10 4 C64766 40.0 22.5 10 4 C65746 17.5 13.0 10 4 C65990 19.6 15.1 10 Tri-val N4CT1(6)GP(a1) 7.5 x 102 5 0912042 40.7 15.9 10 5 C66003 23.4 17.2 10 5 C68289 19.0 17.0 10 5 C69965 35.6 10.5 10 N4CT1-HIVgag(s1) 7.5 x 106 6 C66134 20.2 16.8 10 6 C69907 10.9 16.2 10

FiloGP-specific Neutralizing Ab Responses* (PRNT50) at Day 35

* Research assay

slide-33
SLIDE 33

Proprietary and confidential. Do not distribute. | 33

D35 (5wks post immunization) anti-Filo GP IFNg ELISpot response

25 50 75 100 125 150 175 200

0912162 C65665 C62625 C64284 C68268 C69902 C56365 C71818 C65896 C66560 C65897 C64685 C69099 C66181 C65581 C65889 C66095 C64766 C65746 C65990 0912042 C66003 C68289 C69965 C66134 C69907

Zaire GP Sudan GP Marburg GP 25 50 75 100 125 150 175 200 Zaire GP Sudan GP Marburg GP

7.5x106 7.5x105 7.5x104 7.5x103 7.5x102 Con 7.5x106 7.5x105 7.5x104 7.5x103 7.5x102 Con

Total Filo GP-specific IFNg ELISpot Response (SFC/106 PBMCs)

* * * * * * * * * * * ** * * * * * * * * * * *

3/5 (60%) 4/5 (80%) 3/5 (60%) 1/5 (20%) 2/4 (50%) 0/2 (0%)

Responder Freq

A B

slide-34
SLIDE 34

Proprietary and confidential. Do not distribute. | 34

20 40 60 80 100 120 5 10 15 20 25 30

Post Challenge Survival (1,000 PFU AE MARV)

% Survival Day post challenge

10^6 10^5 10^4 &10^3 10^2 & Controls

slide-35
SLIDE 35

Proprietary and confidential. Do not distribute. | 35

Determining a Correlate of Protection against 1,000 PFU AE MARV Challenge

slide-36
SLIDE 36

Proprietary and confidential. Do not distribute. | 0.00 20.00 40.00 60.00 80.00 100.00 120.00 140.00 160.00 C69902 C65665 C68289 0912162 C66134 C65889 C65896 C64685 C66560 C69099 C65581 C64284 0912042 C71818 C65897 C66095 C69965 C65746 C66181 C64766 C62625 C68268 C56365 C65990 C69907 C66003

‡ not challenged

36

† † † † † † † † † † † † † † † † †

D35 Anti-MARV ELISpot Response (SFC/10^6 PBMCs)

Relationship between D35 anti-MARV ELISpot response and post challenge outcome

S S S S S S S S

slide-37
SLIDE 37

Proprietary and confidential. Do not distribute. | 37 5 10 15 20 25 30 35 40 0912162 C65665 C56365 C65896 C66560 C64284 C69902 C62625 C68268 C71818 C65897 C64685 C69099 C66181 C65581 C65889 C66095 C64766 C65746 C65990 0912042 C66003 C68289 C69965 C66134 C69907

† † † † † † † † † † † † † † † † † D35 Anti-MARV Neut Ab titers

Relationship between D35 anti-MARV Neut Ab titer and post challenge outcome

‡

‡ not challenged

S S S S S S S S

slide-38
SLIDE 38

Proprietary and confidential. Do not distribute. | 50 100 150 200 250 300 350 400 450 0912162 C65665 C69902 C64284 C62625 C56365 C65889 C68268 C71818 C64685 C65896 C65897 C66095 0912042 C66181 C65581 C66560 C64766 C69099 C65746 C65990 C66003 C68289 C69965 C66134 C69907

38

† † † † † † † † † † † † † † † † †

Not challenged

D35 Anti-MARV ELISA titers

Relationship between D35 anti-MARV ELISA titer and post challenge outcome

* * S S S S S S S S

slide-39
SLIDE 39

Proprietary and confidential. Do not distribute. |

Univariate Logistic Regression Models Fitted to Immune Response Data

Only MARV GP-specific ELISA responses at study days 28 and 35 (p-values = 0.0078 and 0.0061, respectively) were shown to be significantly associated with survival

39

slide-40
SLIDE 40

Proprietary and confidential. Do not distribute. | 40

Using an Immune Correlate to Gauge Potential Protective Efficacy of a Vaccine in Ph I/II Clinical samples

  • Extrapolate an “threshold”

MARV GP-specific ELISA response associated with 80%, 90% or 95% probability of survival

  • Experimental vaccines

capable of eliciting and / or maintaining an immune response above a pre- defined “protective” level might be expected to be efficacious and would warrant additional development

slide-41
SLIDE 41

Proprietary and confidential. Do not distribute. |

Presentation Outline:

1.) Background on the VesiculoVax™ Vaccine Platform 2.) Ability of a Single Dose Tri-valent VesiculoVax™ panFilo Vaccine to protect against EBOV, SUDV and MARV challenge 3.) Phase I Safety and Immunogenicity of the mono-valent VesiculoVax™ EBOV Vaccine 4.) Identification of a Correlate of Protection Against Aerosol MARV challenge in NHPs 5.) Future Plans

41

slide-42
SLIDE 42

Proprietary and confidential. Do not distribute. |

Phase 1 Dose Escalation and Vaccination Schedule in Months (Days) Study Arm N Total Dose Month 0 (Day 0) Month 1 (Day 28) Month 1 (Day 56) Cohort 1 10 2.5 x 104 PFU rVSVN4CT1-MARVGP1 — rVSVN4CT1-MARVGP1 3 — control (saline) — control (saline) Cohort 2 10 2.5 x 105 PFU rVSVN4CT1-MARVGP1 — rVSVN4CT1-MARVGP1 3 — control (saline) — control (saline) Cohort 3 10 2.0 x 106 PFU rVSVN4CT1-MARVGP1 — rVSVN4CT1-MARVGP1 3 — control (saline) — control (saline) Cohort 4 10 2.0 x 106 PFU rVSVN4CT1-MARVGP1 rVSVN4CT1-MARVGP1 — 3 — control (saline) control (saline) — Total 52 (40 vaccine/12 placebo) PFU = plaques forming units.

rVSV-MARV-01: Marburg Vaccine Phase I Study

42

slide-43
SLIDE 43

Proprietary and confidential. Do not distribute. |

Work in-progress:

  • Development of a VesiculoVax™ Vaccine with >2 yr shelf life at room

temperature

  • rVSV-EBOV and rVSV-MARV lyophilized with ~75% retention of potency
  • rVSV-SUDV lyophilization development in progress
  • Development of a Quadra-valent VesiculoVax™ panFilo/Lassa Vaccine
  • rVSVN4CT1-EBOV/SUDV/MARV/LASV has entered animal testing

43

slide-44
SLIDE 44

Proprietary and confidential. Do not distribute. |

  • Jack Rose

NIH/NIAID NO1-AI-50010 NO1-AI-05397 RO1-AI-098817

  • Tony Conley
  • Michael Pensiero
  • Pat Repik
  • Heinz Feldmann
  • Andrea Marzi
  • Michael Egan
  • Rong Xu
  • Ayuko Ota-Setlik
  • Luz Hermeda
  • Amara Luckay
  • Hinna Akhtar
  • David Clarke
  • Stefan Hamm
  • Demetrius Matassov
  • Terri Latham
  • Becky Nowak
  • Cheryl Kotash
  • Daniel Colon
  • Luke Jasenosky
  • Susan Witko
  • Tracy Chen
  • Marc Tremblay
  • Alan Gordon
  • Jeff Meshulam
  • Loema Titanji
  • Greg Goffreda
  • Susan Sciotto-

Brown

  • Edens Lamarre

Acknowledgements

  • Thomas Geisbert
  • Joan Geisbert
  • K Agans
  • Chad Mire
  • K Fenton
  • Nicole Kilgore
  • Christopher Dorsey
  • Callie Bounds
  • Lucy Ward
  • Chris Badorrek
  • Clint Florence
  • Janice Rusnak
  • Amanda Burnaugh
  • Carol Sabourin
  • J Price
  • T Rudge
  • Amanda Zarrabian
  • Eric Espland

44 John Eldridge, CSO JPEO

slide-45
SLIDE 45

Proprietary and confidential. Do not distribute. |

The Profectus Ebola vaccine programs are supported by the U.S. Department

  • f Defense Medical Countermeasures Systems–Joint Program Executive Office

for Chemical and Biological Defense (JPEO-CBD) and Joint Vaccine Acquisition Program (MCS-JVAP) both directly and through contracts with Battelle, the Biomedical Advanced Research and Development Authority (BARDA), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Acknowledgements

45